Contents

Bimatoprost implant

Edited by:

Last updated: February 8th, 2022

Menu

Summary of Evidence

Latanoprost implant vs Timolol

Bimatoprost implants (10- and 15-μg) were non-inferior to timolol in IOP-lowering through week 12.(ARTEMIS, 2020) {Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, Guo Q, Zhang J, Robinson MR, Weinreb RN; ARTEMIS 1 Study Group. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology. 2020 Dec;127(12):1627-1641.}

Evidence

1. Background

2. Safety and efficacy

2.1 Comparative effectiveness

2.1.1 Bimatoprost implant vs Timolol

Clinical Trial

2020 Medeiros et.al. (ARTEMIS)

Article link | Archive link | Metrics cited by count

2020
Clinical Trial

Bimatoprost implants (10- and 15-μg) were non-inferior to timolol in IOP-lowering through week 12. {Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, Guo Q, Zhang J, Robinson MR, Weinreb RN; ARTEMIS 1 Study Group. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology. 2020 Dec;127(12):1627-1641.}

  • Randomized controlled trial of bimatoprost implant (10- and 15-μg) vs timolol in patients with bilateral open angle glaucoma or ocular hypertension (594 patients)
  • Findings:
    • Both dose strengths (10- and 15-μg) of bimatoprost implant were noninferior to timolol in IOP lowering after each administration.
    • The incidence of corneal and inflammatory treatment-emergent adverse events of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol, and highest with the 15-μg dose strength.
Outcomes Bimatoprost implant 10-μg Bimatoprost implant 15-μg Timolol
Mean baseline IOP 24.0 24.2 23.9
Mean IOP at week 12 16.5-17.2 16.5-17.0 17.1-17.5
≥20% corneal endothelial cell density loss at month 20 10.2% 21.8%

Medeiros et.al. (ARTEMIS)
Journal full text Archive Metrics

cited by count

References

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

© 2025 - sourceshed